Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicine for treating age-related macular degeneration

A technology related to macular degeneration, applied in the biological field, to reduce costs, prevent retinal dry macular degeneration, and prevent disease progression

Pending Publication Date: 2021-06-29
SHENZHEN TEAMEDON BIOTECHNOLOGY CO LTD
View PDF8 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, considering the role of complement activation in the progression of dry AMD, some complement inhibitors may be effective in the treatment of dry AMD

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine for treating age-related macular degeneration
  • Medicine for treating age-related macular degeneration
  • Medicine for treating age-related macular degeneration

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0050] Example 1 A kind of gene therapy drug for treating age-related macular degeneration

[0051] The medicine is directly linked into a fusion protein by the vascular endothelial growth factor (VEGF) inhibitory protein Aflibercept and the complement inhibitory protein CD59, the amino acid sequence of the fusion protein is shown in SEQ ID NO.3, and the nucleotide encoding the fusion protein The sequence is shown in SEQ ID NO.4.

[0052] >SEQ ID NO.3

[0053] MVSYWDTGVLLCALLSCLLLTGSSSGSDTGRPFVEMYSEIPEIIHMTEGRELVIPCRVTSPNITVTLKKFPLDTLIPDGKRIIWDSRKGFIISNATYKEIGLLTCEATVNGHLYKTNYLTHRQTNTIIDVVLSPSHGIELSVGEKLVLNCTARTELNVGIDFNWEYPSSKHQHKKLVNRDLKTQSGSEMKKFLSTLTIDGVTRSDQGLYTCAASSGLMTKKNSTFVRVHEKDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKLQCYNCPNPTADCKTAVNCSSDFDACLITKAGLQVYNKCWKFEHCNFNDVTTRLRENELTYYCCKKDL...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the technical field of biology, and particularly relates to a medicine for treating age-related macular degeneration, the medicine is a fusion protein composed of vascular endothelial growth factor inhibitory protein and complement inhibitory protein, and the medicine can be used for treating diseases caused by vascular endothelial growth factor and / or complement activation. The fusion protein can be administered in various modes, and the specific forms include but are not limited to recombinant protein, genes for directly delivering and coding the fusion protein through a nano material wrapping technology, and genes for directly delivering and coding the fusion protein through various virus vectors. The medicine disclosed by the invention belongs to gene therapy, can stably release the medicine, does not generate violent fluctuation of intraocular medicine concentration in a treatment cycle, only needs to be injected once, reduces the frequency of patients going to hospitals, can prevent wet macular degeneration from being converted into dry macular degeneration, and eliminates treatment hidden dangers.

Description

technical field [0001] The invention belongs to the field of biotechnology, in particular to a medicine for treating age-related macular degeneration. Background technique [0002] Age-related macular degeneration (AMD) is a common geriatric disease characterized by central vision blurring and is the leading cause of blindness in people over 50 years of age. According to the course of the disease, it can be divided into three types: early, middle and late. In the late stage, it is divided into two types: "dry" and "wet". Dry age-related macular degeneration (dryAMD) accounts for about 90% of the total AMD, and the remaining about 10% is wet age-related macular degeneration (wetAMD). Both types of AMD have complex etiologies, including genetic factors. For wet AMD, a relatively clear reason is that vascular endothelial growth factor (VEGF) promotes the active generation of new blood vessels under the pigment epithelium, which causes a series of exudation, bleeding, and sca...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K48/00A61K38/17A61K9/00A61P9/10A61P27/02C07K19/00B82Y5/00B82Y40/00
CPCA61K48/005C07K14/70596C07K14/71A61K48/0008A61K38/179A61K38/177A61K9/0019A61K9/0048A61P27/02A61P9/10B82Y5/00B82Y40/00C07K2319/00C07K2319/30
Inventor 牟学延来大志熊燃邓唯珂
Owner SHENZHEN TEAMEDON BIOTECHNOLOGY CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com